Beijing Beilu Pharmaceutical Co., Ltd. (300016)
XSHE XSHE Primary Summary
Beijing Beilu Pharmaceutical Co., Ltd. (300016) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Beijing Beilu Pharmaceutical Co., Ltd. ever had a stock split?
Beijing Beilu Pharmaceutical Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Xu Wang CEO | XSHE Exchange | CNE000001QK9 ISIN |
| CN Country | 1,173 Employees | 19 May 2025 Last Dividend | 4 Sep 2018 Last Split | 30 Oct 2009 IPO Date |
Overview
Beijing Beilu Pharmaceutical Co., Ltd. is a distinguished entity in the pharmaceutical landscape of China, focusing on the research, development, production, and sale of a wide array of pharmaceutical products. Since its inception in 1992, the company has embarked on a journey of innovation in the pharmaceutical field from its headquarters in Beijing, China. It stands out for its dedicated efforts in producing precision medicine, leveraging cutting-edge technologies to cater to specific patient needs, thereby embodying the future of personalized healthcare. Through its enduring commitment to quality and innovation, Beijing Beilu Pharmaceutical Co., Ltd. aims to contribute significantly to the pharmaceutical industry, ensuring better health outcomes for individuals and communities alike.
Products and Services
- Contrast Agents
- Central Nervous System Products
- Oral Anti-Diabetic Drugs
- Precision Medicine
Beijing Beilu Pharmaceutical Co., Ltd. develops and markets a range of contrast agents used in medical imaging to enhance the visibility of tissues, organs, and blood vessels. These products are essential in diagnostic radiology, assisting clinicians in making more accurate diagnoses and determining the most appropriate treatment plans for various conditions.
The company offers a comprehensive portfolio of central nervous system (CNS) products. These medications are designed to address a spectrum of neurologic and psychiatric conditions, exemplifying the company’s commitment to addressing complex healthcare challenges through innovative pharmaceutical solutions.
A key area of focus for Beijing Beilu Pharmaceutical Co., Ltd. is the development and sale of oral anti-diabetic drugs. These medications play a crucial role in managing diabetes mellitus, helping to control blood sugar levels and prevent complications associated with the condition. The availability of such drugs underscores the company's dedication to fighting one of the most prevalent chronic diseases globally.
Beijing Beilu Pharmaceutical Co., Ltd. pioneers in the realm of precision medicine, offering treatments tailored to the genetic makeup of individual patients. This revolutionary approach to healthcare emphasizes the creation of medications that achieve the highest levels of efficacy by accounting for genetic differences among individuals. Its commitment to precision medicine highlights the company’s role in leading the next wave of pharmaceutical innovation aimed at providing more personalized and effective healthcare solutions.
